Q-omics provides the consensus-scored PADI2 profile across patient tissues and cancer cell-line models. PADI2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, PADI2 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, PADI2 protein abundance shows 23,484 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, COAD, and GBM as cancer lineages where PADI2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PADI2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PADI2 survival associations across molecular data types. PADI2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PADI2 RNA expression–survival associations across cancer types. High PADI2 expression shows unfavorable associations in LGG, OV, ESCA, MESO and SCLC, but favorable associations in READ. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for PADI2 RNA expression.
This table summarizes PADI2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PADI2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PADI2 shows lower tumor expression in COAD, KICH, KIRC, KIRP, HNSC and BRCA. The COAD box plot shows higher PADI2 RNA expression in normal versus tumor tissue (log2 FC = −3.744, t-test p < 0.001).
This table shows molecular features associated with PADI2 in patient tissues and cancer cell lines. In patient samples, PADI2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PADI2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
